210
S. James
27. Wei G, Wang Y, Huang X, Hou H, Zhou S (2018) Peptide-based nanocarriers for cancer therapy.
Small Methods 2:1700358. https://doi.org/10.1002/smtd.201700358
28. Dos Santos Rodrigues B, Lakkadwala S, Kanekiyo T, Singh J (2019) Development and
screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene
delivery properties. Int J Nanomedicine 14:6497–6517. https://doi.org/10.2147/IJN.S215941
29. Libutti SK, Paciotti GF, Myer L, Haynes R, Gannon W, Walker M, Seidel G, Byrnes A,
Yuldasheva N, Tamarkin L (2009) Results of a completed phase I clinical trial of CYT-6091:
a pegylated colloidal gold-TNF nanomedicine. J Clin Oncol
30. Chen G, Karzai F, Madan RA, Cordes LM, Bilusic M, Owens H, Hankin A, Williams M,
Couvillon A, Gulley JL, Dahut WL, Thomas A (2018) CRLX101 plus olaparib in patients with
metastatic castration-resistant prostate cancer. J Clin Oncol. https://doi.org/10.1200/jco.2018.
36.15_suppl.tps5096
31. Atrafi F, Dumez H, Mathijssen RHJ, Menke CW, Costermans J, Rijcken CJF, Hanssen R,
Eskens F, Schoffski P (2019) A phase I dose-finding and pharmacokinetics study of CPC634
(nanoparticle entrapped docetaxel) in patients with advanced solid tumors. J Clin Oncol. https://
doi.org/10.1200/jco.2019.37.15_suppl.3026
32. Trafton A (2018) Tiny particles could help fight brain cancer. MIT News
33. Amini MA, Abbasi AZ, Cai P, Lip HY, Gordijo CR, Li J, Chen B, Zhang L, Rauth AM, Yu
WuX (2019) Combining tumor microenvironment modulating nanoparticles with doxorubicin
to enhance chemotherapeutic efficacy and boost antitumor immunity. J Natl Cancer Inst. https://
doi.org/10.1093/jnci/djy131
34. Souto EB, Souto SB, Campos JR, Severino P, Pashirova TN, Zakharova LY, Silva AM, Durazzo
A, Lucarini M, Izzo AA, Santini A (2019) Nanoparticle Delivery Systems in the treatment of
diabetes complications. Mol 24:4209. https://doi.org/10.3390/molecules24234209
35. Lipani L, Dupont BGR, Doungmene F, Marken F, Tyrrell RM, Guy RH, Ilie A (2018) Noninvasive, transdermal, path-selective and specific glucose monitoring via a graphene-based
platform. Nat Nanotechnol 13:504–511. https://doi.org/10.1038/s41565-018-0112-4
36. Ramanathan S, Archunan G, Sivakumar M, Tamil Selvan S, Fred AL, Kumar S, Gulyás
B, Padmanabhan P (2018) Theranostic applications of nanoparticles in neurodegenerative
disorders. Int J Nanomed 13:5561–5576. https://doi.org/10.2147/IJN.S149022
37. Alzheimer’s facts and figures report
38. Kaur IP, Bhandari R, Bhandari S, Kakkar V (2008) Potential of solid lipid nanoparticles in
brain targeting. J. Control Release
39. Costa PM, Wang JT-W, Morfin J-F, Khanum T, To W, Sosabowski J, Tóth E, Al-Jamal KT
(2018) Functionalised carbon nanotubes enhance brain delivery of amyloid-targeting Pittsburgh Compound B (PiB)-derived ligands. Nanotheranostics 2:168–183. https://doi.org/10.
7150/ntno.23125
40. Ambesh P, Campia U, Obiagwu C, Bansal R, Shetty V, Hollander G, Shani J (2017)
Nanomedicine in coronary artery disease. Indian Heart J
S. James
27. Wei G, Wang Y, Huang X, Hou H, Zhou S (2018) Peptide-based nanocarriers for cancer therapy.
Small Methods 2:1700358. https://doi.org/10.1002/smtd.201700358
28. Dos Santos Rodrigues B, Lakkadwala S, Kanekiyo T, Singh J (2019) Development and
screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene
delivery properties. Int J Nanomedicine 14:6497–6517. https://doi.org/10.2147/IJN.S215941
29. Libutti SK, Paciotti GF, Myer L, Haynes R, Gannon W, Walker M, Seidel G, Byrnes A,
Yuldasheva N, Tamarkin L (2009) Results of a completed phase I clinical trial of CYT-6091:
a pegylated colloidal gold-TNF nanomedicine. J Clin Oncol
30. Chen G, Karzai F, Madan RA, Cordes LM, Bilusic M, Owens H, Hankin A, Williams M,
Couvillon A, Gulley JL, Dahut WL, Thomas A (2018) CRLX101 plus olaparib in patients with
metastatic castration-resistant prostate cancer. J Clin Oncol. https://doi.org/10.1200/jco.2018.
36.15_suppl.tps5096
31. Atrafi F, Dumez H, Mathijssen RHJ, Menke CW, Costermans J, Rijcken CJF, Hanssen R,
Eskens F, Schoffski P (2019) A phase I dose-finding and pharmacokinetics study of CPC634
(nanoparticle entrapped docetaxel) in patients with advanced solid tumors. J Clin Oncol. https://
doi.org/10.1200/jco.2019.37.15_suppl.3026
32. Trafton A (2018) Tiny particles could help fight brain cancer. MIT News
33. Amini MA, Abbasi AZ, Cai P, Lip HY, Gordijo CR, Li J, Chen B, Zhang L, Rauth AM, Yu
WuX (2019) Combining tumor microenvironment modulating nanoparticles with doxorubicin
to enhance chemotherapeutic efficacy and boost antitumor immunity. J Natl Cancer Inst. https://
doi.org/10.1093/jnci/djy131
34. Souto EB, Souto SB, Campos JR, Severino P, Pashirova TN, Zakharova LY, Silva AM, Durazzo
A, Lucarini M, Izzo AA, Santini A (2019) Nanoparticle Delivery Systems in the treatment of
diabetes complications. Mol 24:4209. https://doi.org/10.3390/molecules24234209
35. Lipani L, Dupont BGR, Doungmene F, Marken F, Tyrrell RM, Guy RH, Ilie A (2018) Noninvasive, transdermal, path-selective and specific glucose monitoring via a graphene-based
platform. Nat Nanotechnol 13:504–511. https://doi.org/10.1038/s41565-018-0112-4
36. Ramanathan S, Archunan G, Sivakumar M, Tamil Selvan S, Fred AL, Kumar S, Gulyás
B, Padmanabhan P (2018) Theranostic applications of nanoparticles in neurodegenerative
disorders. Int J Nanomed 13:5561–5576. https://doi.org/10.2147/IJN.S149022
37. Alzheimer’s facts and figures report
38. Kaur IP, Bhandari R, Bhandari S, Kakkar V (2008) Potential of solid lipid nanoparticles in
brain targeting. J. Control Release
39. Costa PM, Wang JT-W, Morfin J-F, Khanum T, To W, Sosabowski J, Tóth E, Al-Jamal KT
(2018) Functionalised carbon nanotubes enhance brain delivery of amyloid-targeting Pittsburgh Compound B (PiB)-derived ligands. Nanotheranostics 2:168–183. https://doi.org/10.
7150/ntno.23125
40. Ambesh P, Campia U, Obiagwu C, Bansal R, Shetty V, Hollander G, Shani J (2017)
Nanomedicine in coronary artery disease. Indian Heart J